MYD88 and metabolic dysfunction-associated steatohepatitis: Subsequent barrier dysfunction exposes the liver to dual insults: endotoxin assault and persistent gut-derived pathogen-associated molecular patterns, mechanistically explaining the characteristic TLR4/MyD88 pathway hyperactivation in non-alcoholic steatohepatitis (NASH) patients (Si et al., 2022).